All In Biotech

Drug Trial Radar · NCT05990543

Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer

Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer With Resistance or Intolerance to Oxaliplatin and Irinotecan-based Chemotherapy - A Single Arm, Phase 1b/2, Multicenter Study

Last checked: Nov 20, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

59

Planned (sponsor's estimate)

Start

Jan 29, 2024

Primary completion

Dec 1, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Korea University Anam HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label clinical trial aimed at evaluating the safety and efficacy of the combination treatment of nelmastobart with capecitabine in patients diagnosed with metastatic or recurrent colorectal cancer.

Conditions

  • Recurrent or Metastatic Colorectal Cancer

Interventions

  • Nelmastobart and CapecitabineDrug

    Nelmastobart intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered on Day 1 of each cycle. Capecitabine is administered orally for two weeks followed by a one-week rest period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated DoseTime frame: Up to approximately 2 years
  2. Progression free survivalTime frame: Up to approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University Medical Center 73, Goryeodae-ro, Seongbuk-gu

    Seoul, Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.